JB Pharma reports strong Q2 FY26 performance with double-digit profit growth

J.B. Chemicals & Pharmaceuticals (JB Pharma) announced robust financial results for Q2 FY26, with revenue growing 8% to INR 1,085 crores from INR 1,001 crores in Q2 FY25. Operating EBITDA increased by 12% to INR 319 crores (from INR 285 crores), and net profit rose 19% to INR 208 crores (from INR 175 crores). Domestic formulations achieved 9% year-over-year growth to INR 644 crores, while international business grew 7% to INR 441 crores.

The company's domestic business continued to outperform the market, with key brands like Cilacar, Metrogyl, and Nicardia gaining ranks. The Razel franchise surpassed INR 100 crores in sales, growing 12% year-over-year. Acquired portfolios also demonstrated strong growth, with the Sporlac franchise nearly doubling in three years to INR 153 crores.

Internationally, CDMO business saw a 20% growth to INR 113 crores, backed by a strong order book, while API business generated INR 22 crores. The ophthalmology portfolio, acquired from Novartis, progressed well post-integration in January 2024, contributing INR 115 crores in H1 FY26.